Anika Therapeutics Inc (ANIK)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ANIK
Anika Therapeutics Inc
$20.86
-0.62%
HEALTHCARE · Cap: $279.17M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.26
+0.83%
HEALTHCARE · Cap: $58.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 3828148% more annual revenue ($4.62T vs $120.65M). ANIK leads profitability with a -3.1% profit margin vs -3.5%. TAK appears more attractively valued with a PEG of 0.43. TAK earns a higher WallStSmart Score of 53/100 (C-).
ANIK
Hold39
out of 100
Grade: F
TAK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.8%
Fair Value
$32.86
Current Price
$20.86
$12.00 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Reasonable price relative to book value
15.6% revenue growth
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of -8.3% — below average capital efficiency
Earnings declined 50.5%
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIK
The strongest argument for ANIK centers on Altman Z-Score, Debt/Equity, Price/Book. Revenue growth of 15.6% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.43 suggests the stock is reasonably priced for its growth.
Bear Case : ANIK
The primary concerns for ANIK are PEG Ratio, Market Cap, Return on Equity.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ANIK profiles as a growth stock while TAK is a turnaround play — different risk/reward profiles.
ANIK carries more volatility with a beta of 0.20 — expect wider price swings.
ANIK is growing revenue faster at 15.6% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (53/100 vs 39/100) and 10.2% revenue growth. ANIK offers better value entry with a 68.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anika Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?